
(© vaaseenaa - stock.adobe.com)
In A Nutshell
- A new analysis of seven clinical trials found that plant-based diets were linked to lower levels of CRP, a blood marker tied to inflammation and heart disease risk.
- Participants who followed plant-based eating patterns showed an average CRP reduction of about 1 milligram per liter compared to those eating standard meat-containing diets.
- That drop could be meaningful: CDC and American Heart Association guidelines use CRP thresholds to classify people as low, average, or high risk for cardiovascular events.
- The evidence is promising but limited: only 541 people were studied across all seven trials, certainty was rated low, and researchers say larger studies are still needed.
A quiet kind of inflammation often rises as people get older, and it’s linked to heart disease, diabetes, and cancer. Scientists call it “inflammageing.” Now, a new analysis of clinical trials suggests that shifting toward a plant-based diet could help tamp down that slow burn, lowering a blood marker tied to inflammation and heart disease risk.
Published in the journal Nutrition, Metabolism and Cardiovascular Diseases, the study is the first analysis to rely exclusively on randomized controlled trials, a stronger type of evidence than observational diet studies, to examine whether plant-based diets can reduce levels of C-reactive protein (CRP), a marker of inflammation in the blood. After pooling data from seven trials involving 541 participants, researchers at the University of Warwick found that people who followed plant-based eating patterns had lower CRP levels than those eating standard diets that included meat.
CRP is an independent predictor of future heart attacks and strokes. One major study found that cardiovascular disease risk jumped by 50 percent as baseline CRP rose. With cardiovascular disease a leading cause of death worldwide, a diet-linked drop in CRP is worth studying closely, especially in larger trials.
How Plant-Based Diets Were Tested Against Inflammation
Researchers Luke Bell, Joshua Gibbs, and Francesco P. Cappuccio searched three major medical databases for controlled trials that compared a plant-based diet to a standard meat-containing diet and measured CRP levels. Out of nearly 3,000 studies initially identified, only seven met their strict criteria. Those seven trials, published between 1991 and 2024, came from the United States, the Netherlands, Czechia, Norway, and Sweden. Participants had a median age of 55 and included people with conditions ranging from type 2 diabetes and rheumatoid arthritis to heart disease and obesity, a detail worth noting, since pre-existing health conditions can heavily influence baseline CRP levels.
The plant-based diets in these trials varied. Some were fully vegan. Others allowed eggs and dairy but no meat or seafood. A third category was what researchers called a “wholefood, plant-based diet,” defined in the study as predominantly plant-based but permitting small amounts of animal products, specifically no more than 25 percent of daily calories from animal sources. Control groups ate a range of standard diets, including their usual meals or diets recommended by the American Heart Association.
Trial durations ranged from 4 weeks to 52 weeks. After pooling the results, plant-based eating was associated with a CRP reduction of 1.13 milligrams per liter compared to standard diets. Diet alone produced a reduction of 0.94 milligrams per liter; when combined with exercise, that figure rose to 1.46 milligrams per liter, though the small number of trials means the combined result should be read carefully.

Why a Drop in CRP From a Plant-Based Diet Matters
Guidelines from the CDC and American Heart Association classify CRP levels below 1 milligram per liter as low risk, between 1 and 3 as average risk, and above 3 as high risk for future cardiovascular events. People in the highest category face roughly double the risk compared to those in the lowest. A recent analysis also found that each 1 milligram-per-liter increase in CRP was associated with a 10 percent higher risk of heart failure, at least for patients with CRP levels up to 20 milligrams per liter.
So a reduction of around 1 milligram per liter, as seen in this analysis, could potentially shift some people from a higher-risk category to a lower one.
Why plant-heavy diets might lower inflammation isn’t fully pinned down, but a few plausible pathways exist. Plant-based diets tend to be richer in flavonoids, found in berries and tea, and carotenoids, found in carrots and tomatoes, both linked to lower CRP in previous research. Lower saturated fat intake may also play a role, since saturated fat, abundant in animal products, has been associated with higher CRP levels.
Plant-Based Diet Study Caveats Worth Knowing
Only seven trials qualified, with just 541 participants total, a small pool. Variability between studies was high. One trial from Norway, involving patients with rheumatoid arthritis, was weighted at over 50 percent of the entire analysis and had far higher baseline CRP values than other included studies. Because rheumatoid arthritis itself drives elevated inflammation, that single trial’s outsized influence is an important caveat. When it was removed, variability dropped sharply, though the overall finding of a CRP reduction still held.
Another built-in challenge in diet research is that it’s effectively impossible to blind participants. People know whether they’re eating steak or lentils, which makes every included study vulnerable to a type of bias that tightly controlled drug trials can avoid. Certainty of the overall findings was rated as low.
Cardiovascular disease is linked to inflammation, and this small analysis suggests plant-based diets may reduce one commonly used inflammation marker. Seven trials and 541 participants aren’t enough to rewrite dietary guidelines, and the authors are clear-eyed about that. But the case for running larger, longer, and more diverse trials has rarely looked stronger.
Disclaimer: This article is based on published research and is intended for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making changes to your diet or health routine.
Paper Notes
Limitations
The researchers identified several important limitations. Only seven randomized controlled trials met the inclusion criteria, yielding a total sample size of just 541 participants, which limits statistical power. Heterogeneity between studies was high (I² = 86% in the main analysis), and the certainty of findings was rated as low using the GRADE framework. One study (Kjeldsen-Kragh et al.) was identified as the principal source of heterogeneity and was weighted at over 50 percent of the main analysis; its participants had rheumatoid arthritis and baseline CRP values far higher than those in other trials. Blinding participants in dietary trials is effectively impossible, meaning all included studies were at high risk of performance bias. The intervention diets varied in composition across studies, and the small number of trials precluded meaningful subgroup analyses by specific diet type. None of the trials reported results stratified by biological sex. The number of included studies fell below the Cochrane Handbook’s recommended minimum of 10 for formal publication bias testing or meta-regression, so those exploratory analyses should be interpreted with caution.
Funding and Disclosures
The research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declared no conflict of interest.
Publication Details
Authors: Luke Bell, Joshua Gibbs, Francesco P. Cappuccio | Affiliations: World Health Organisation Collaborating Centre for Nutrition, University of Warwick, Warwick Medical School, Applied Health, Coventry, UK; University Hospitals Coventry & Warwickshire NHS Trust, Coventry, UK | Journal: Nutrition, Metabolism and Cardiovascular Diseases | Title: “The effect of plant-based dietary patterns on C-reactive protein: A systematic review and meta-analysis of randomised controlled trials” | DOI: https://doi.org/10.1016/j.numecd.2026.104631 | Received: 20 October 2025; Accepted: 12 February 2026; Available online: 18 February 2026 | PROSPERO Registration: CRD420251136692 | License: Open access under CC BY 4.0







